Abstract P2-06-06: A clinical model for assessment of the individual breast cancer risk

Conclusions: Our data demonstrate that estrogen and ERβ-specific agonists cause cell cycle arrest in ERβ positive TNBC. These effects are due to ERβ-mediated suppression of multiple genes involved in cell cycle progression including CDK1 and Cyclin B. Following knockdown of CDK1, estrogen or ERβ-specific agonist treatment displayed minimal impact on cell proliferation. Therefore, ERβ's effects on proliferation may primarily be mediated by blockade of CDK1 and Cyclin B. Regardless of ERβ, our data suggest that inhibition of CDK1 activity may have therapeutic benefit in a subset of TNBC patients, an area of study that has yet to be explored.Citation Format: Eriksson M, Czene K, Pawitan Y, Leifland K, Darabi H, Hall P. A clinical model for assessment of the individual breast cancer risk [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-06-06.

Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: M Eriksson, K Czene, Y Pawitan, K Leifland, H Darabi, P Hall Tags: Poster Session Abstracts Source Type: research